[Effects erythropoietin on experimental anemia in rats with chronic renal failure].
Erythropoietin (EPO) is a glycoprotein hormone secreted by human kidney cells. Human EPO was induced from human embryo kidney cells, isolated and purified from medium by biochemical method in our laboratory. The hypoproliferative anemia in chronic renal failure (CRF) has been assumed to be the result of decreased EPO production by the damaged kidney and of the shortening of the survival of erythrocytes. In this study, CRF anemia was formed 9 weeks after the removal of five-sixths of the renal mass of rats. These anemic rats were divided into 6 groups: treated with different dosages of EPO or physiological saline. The results indicate that EPO has apparent effects on anemia in rats with CRF. It may stimulate erythropoiesis and improve the anemia state of rats with CRF. Hematological parameters (RBC, Hb, PLT, Ht and Rt) may be reverted to normal levels (P less than 0.001). The level of BUN and Cr were significantly decreased. The optimum dose of EPO was 1000 U/kg. All these results show that injection of EPO has therapeutic effect on anemia in rats with CRF. EPO showed no effect on normal rats.
Ling
S S
SS
Department of Pharmacology, General Hospital of Nanjing Command, PLA.
Zhou
Y
Y
Sun
W L
WL
Zhu
D C
DC
Zhang
H Y
HY
Tang
G Z
GZ
Jin
Y F
YF
Zhu
J Z
JZ
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D009392:Nephrectomy / Q000379:methods; D051381:Rats; D011919:Rats, Inbred Strains
D004921:Erythropoietin